Mark Fladrich

Président chez MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

67 ans

Health Technology

Consumer Services

Distribution Services

Profil

Mark Fladrich is currently Chairman at Qbiotics Pty Ltd., Chairman at Grünenthal Pharma SA since 2018, Chairman at Medical Developments International Ltd. starting in 2025, and Director at Grünenthal Ltd. since 2018.
Formerly, Mr. Fladrich was Chief Commercial Officer at Grünenthal GmbH.
Education includes an MBA from Macquarie University and an undergraduate degree from the University of South Australia.

Postes actifs de Mark Fladrich

Sociétés	Poste	Début
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED	Président	01/12/2025
Grünenthal Pharma SA Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines	Président	23/03/2018
Grünenthal Ltd. Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products	Directeur/Membre du Conseil	18/01/2018
Qbiotics Pty Ltd. Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers.	Président	-

Tous les postes actifs de Mark Fladrich

Anciens postes connus de Mark Fladrich

Sociétés	Poste	Fin
Grünenthal GmbH Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases	Corporate Officer/Principal	-

Voir l'expérience en détail de Mark Fladrich

Formation de Mark Fladrich

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Mark Fladrich

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	7
Medical Developments International Ltd. Medical Developments International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical drugs & medical equipment	Health Technology
Grünenthal GmbH Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases	Health Technology
Macquarie University Macquarie University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of South Australia University of South Australia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Grünenthal Ltd. Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products	Distribution Services
Grünenthal Pharma SA Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines	Health Technology
Qbiotics Pty Ltd. Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers.